(2R)-2-octanoylamino-2-phenylethanol | 289051-69-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R)-2-octanoylamino-2-phenylethanol
• 英文别名: N-[(1R)-2-hydroxy-1-phenylethyl]octanamide
• CAS: 289051-69-0
• 化学式: C₁₆H₂₅NO₂
• 分子量: 263.38
• InChiKey: JBLMWAWQCNKANA-HNNXBMFYSA-N

物化性质

• 沸点：
  459.4±38.0 °C(Predicted)
• 密度：
  1.018±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R)-2-octanoylamino-2-phenylethanol 在 四氮唑 、 sodium chloride 、 碳酸氢钠 作用下， 以 乙腈 为溶剂， 生成 (2R)-2-Octanoylamino-2-phenylethoxybis(2-cyanoethoxy)phosphine
  参考文献：
  名称：

  Drugs containing phosphoric acid derivatives as the active ingredient

  摘要：

  本发明涉及由通式（I）表示的磷酸衍生物，其中每个符号如描述中所定义及其无毒盐。 由于具有TNF&agr;生产抑制作用，通式（I）表示的化合物可用作类风湿性关节炎、溃疡性结肠炎、克罗恩病、肝炎、败血症、出血性休克、多发性硬化、脑梗死、糖尿病、间质性肺炎、葡萄膜炎、疼痛、肾小球肾炎、艾滋病相关疾病、虚弱、心肌梗死、慢性心力衰竭、口腔溃疡、汉森病、感染等的预防和/或治疗药物。

  公开号：

  US06495533B1
• 作为产物：
  描述：

  D-苯甘氨醇 、 辛酰氯 在 碳酸氢钠 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以85%的产率得到(2R)-2-octanoylamino-2-phenylethanol
  参考文献：
  名称：

  Highly potent inhibitors of TNF-α production. Part I

  摘要：

  Discovery of new chemical leads of inhibitors for TNF-alpha production starting from the chemical modification of I is reported. Further biological studies of 1 to disclose the site of its action strongly suggested that 1 inhibits LPS-induced TNF-alpha expression in the liver and spleen of mice. Structure-activity relationships (SARs) are also discussed and full details including the chemistry are reported. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00381-4

文献信息

• DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1156054A1

  公开（公告）日：2001-11-21

  The present invention relates to phosphoric acid derivatives represented by general formula (I), wherein each symbol is as defined in the description and nontoxic salts thereof. Because of having a TNFα production inhibitory effect, the compounds represented by general formula (I) are useful as preventives and/or remedies for rheumatoid arthritis, ulcerative colitis, Crohn 's disease, hepatitis, sepsis, hemorrhagic shock, multiple sclerosis, cerebral infarction, diabetes, interstitial pneumonia, uveitis, pain, glomerulonephritis, HIV-associated diseases, cachexia, myocardial infarction, chronic heart failure, oral aphtha, Hansen's disease, infection, etc.

  本发明涉及通式(I)代表的磷酸衍生物（其中各符号如描述中所定义）及其无毒盐。 多发性硬化症、脑梗塞、糖尿病、间质性肺炎、葡萄膜炎、疼痛、肾小球肾炎、艾滋病相关疾病、恶病质、心肌梗塞、慢性心力衰竭、口腔阿弗他病、汉森氏病、感染等。
• US6495533B1
  申请人：——

  公开号：US6495533B1

  公开（公告）日：2002-12-17
• Drugs containing phosphoric acid derivatives as the active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US06495533B1

  公开（公告）日：2002-12-17

  The present invention relates to phosphoric acid derivatives represented by general formula (I), wherein each symbol is as defined in the description and nontoxic salts thereof. Because of having a TNF&agr; production inhibitory effect, the compounds represented by general formula (I) are useful as preventives and/or remedies for rheumatoid arthritis, ulcerative colitis, Crohn's disease, hepatitis, sepsis, hemorrhagic shock, multiple sclerosis, cerebral infarction, diabetes, interstitial pneumonia, uveitis, pain, glomerulonephritis, HIV-associated diseases, cachexia, myocardial infarction, chronic heart failure, oral aphtha, Hansen's disease, infection, etc.

  本发明涉及由通式（I）表示的磷酸衍生物，其中每个符号如描述中所定义及其无毒盐。 由于具有TNF&agr;生产抑制作用，通式（I）表示的化合物可用作类风湿性关节炎、溃疡性结肠炎、克罗恩病、肝炎、败血症、出血性休克、多发性硬化、脑梗死、糖尿病、间质性肺炎、葡萄膜炎、疼痛、肾小球肾炎、艾滋病相关疾病、虚弱、心肌梗死、慢性心力衰竭、口腔溃疡、汉森病、感染等的预防和/或治疗药物。
• Highly potent inhibitors of TNF-α production. Part I
  作者：Toshiaki Matsui、Takashi Kondo、Yoshitaka Nishita、Satoshi Itadani、Shingo Nakatani、Nagashige Omawari、Masaru Sakai、Shuichi Nakazawa、Akihito Ogata、Hideaki Mori、Kouichiro Terai、Wataru Kamoshima、Hiroyuki Ohno、Takaaki Obata、Hisao Nakai、Masaaki Toda

  DOI：10.1016/s0968-0896(02)00381-4

  日期：2002.12

  Discovery of new chemical leads of inhibitors for TNF-alpha production starting from the chemical modification of I is reported. Further biological studies of 1 to disclose the site of its action strongly suggested that 1 inhibits LPS-induced TNF-alpha expression in the liver and spleen of mice. Structure-activity relationships (SARs) are also discussed and full details including the chemistry are reported. (C) 2002 Elsevier Science Ltd. All rights reserved.